Mankind Pharma Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
MANKIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Mankind Pharma's promoters, promoter group, and persons acting in concert have filed an annual declaration under SEBI's takeover regulations for the financial year ended March 31, 2025. The filing, signed by promoter Ramesh Juneja, confirms that no encumbrance (such as pledging or hypothecation) was created on the shares held by them in the company, either directly or indirectly, during FY25. A comprehensive list of 86 promoter and promoter group entities, including family trusts, HUFs, LLPs, and private limited companies, was attached as Annexure-1. This is a routine yearly compliance disclosure mandated by SEBI.
This is a neutral-to-positive signal for shareholders — it means the promoter family has not pledged or locked any of their shares as collateral during the year, which is often viewed as a sign of financial stability and confidence in the company.